论文部分内容阅读
目的:评价左氧氟沙星与氨溴索联用治疗肺结核伴肺部感染患者抗感染的临床疗效。方法:选取2015年6月—2016年6月间收治的肺结核伴肺部感染患者100例,采用随机分组法将其分为治疗组和对照组,每组50例;两组患者均给予常规抗结核药物治疗,在此治疗基础上对照组患者加用左氧氟沙星治疗,治疗组患者在对照组治疗基础上加用氨溴索治疗,治疗2周后评价两组患者肺部感染治疗的总有率、不良反应和痰菌(结核分枝杆菌外)转阴率及肺部病灶的吸收率。结果:治疗组患者治疗后的总有效率、痰菌(结核分枝杆菌外)的转阴率、肺部病灶吸收率均优于对照组(P<0.05);用药期间两组患者不良反应的发生率经比较其差异无统计学意义(P>0.05)。结论:采用左氧氟沙星与氨溴索联用治疗肺结核伴肺部感染患者,可以迅速控制肺部感染症状,加速病灶吸收率。用药方便,不良反应较少,疗效安全可靠。
Objective: To evaluate the clinical efficacy of levofloxacin in combination with ambroxol in the treatment of patients with pulmonary tuberculosis and pulmonary infection. Methods: One hundred patients with pulmonary tuberculosis and pulmonary infection who were admitted between June 2015 and June 2016 were selected and randomly divided into treatment group and control group, with 50 cases in each group. Both groups were given routine anti-tuberculosis Tuberculosis drug treatment, based on the treatment of patients with levofloxacin plus treatment group patients in the control group plus ambroxol treatment, after 2 weeks of treatment to evaluate the total rate of pulmonary infection in both groups, Adverse reactions and sputum bacteria (Mycobacterium tuberculosis) negative rate and the absorption rate of lung lesions. Results: The total effective rate, the negative conversion rate of sputum bacteria (outside of Mycobacterium tuberculosis), and the absorption rate of lung lesions in the treatment group were better than those in the control group (P <0.05). The adverse reactions of the two groups The incidence was no significant difference (P> 0.05). Conclusion: The combination of levofloxacin and ambroxol in the treatment of pulmonary tuberculosis patients with pulmonary infection can rapidly control the symptoms of pulmonary infection and speed up the absorption rate of the lesion. Convenient medication, less adverse reactions, safe and reliable.